T 1 hypointense lesions in secondary progressive multiple sclerosis: Effect of interferon beta-1b treatment

Frederik Barkhof, Jan Hein T M Van Waesberghe, Massimo Filippi, Tarek Yousry, David H. Miller, Dietbert Hahn, Alan J. Thompson, Ludwig Kappos, Peter Brex, Carlo Pozzilli, Chris H. Polman

Research output: Contribution to journalArticle

Abstract

Recently, the clinical efficacy of interferon β-1b (IFNβ-1b) was demonstrated for secondary progressive (SP) multiple sclerosis in a European multicentre study. We evaluated the effect of IFNβ-1b treatment on the rate of development of hypointense T 1 MRI lesions, a putative marker of axonal damage. Unenhanced T 1-weighted images were obtained in a subgroup of 95 multiple sclerosis patients from five centres at 6-month intervals; this subgroup was similar to the total study population for all demographic, clinical and MRI parameters. An experienced observer blinded to the clinical data and treatment allocation measured volumes. The median baseline lesion load for hypointense T 1 lesions was 5.1 cm 3 for placebo-treated and 4.9 cm 3 for IFNβ-1b-treated patients (P = 0.56). Placebo-treated patients showed an increase in T 1 lesion load by a median of 14% per year (P = 0.0002 compared with baseline); this was reduced to 7.7% per year in the IFNβ-1b-treated patients (P = 0.003 versus placebo). In the IFNβ-1b arm there was a statistically significant correlation between absolute change in Expanded Disability Status Scale scores and T 1 lesion load by month 36 (r = 0.38, P = 0.0015). In patients with SP multiple sclerosis, IFNβ-1b treatment reduces the development of hypointense T 1 lesions, suggesting that reduced axonal damage in lesions may play a part in the beneficial effect that is observed clinically.

Original languageEnglish
Pages (from-to)1396-1402
Number of pages7
JournalBrain
Volume124
Issue number7
Publication statusPublished - 2001

Fingerprint

Chronic Progressive Multiple Sclerosis
Interferons
Placebos
Therapeutics
Multicenter Studies
Multiple Sclerosis
Interferon beta-1b
Demography
Population

Keywords

  • Black holes
  • Interferon beta
  • Magnetization transfer
  • MRI
  • Multiple sclerosis

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Barkhof, F., Van Waesberghe, J. H. T. M., Filippi, M., Yousry, T., Miller, D. H., Hahn, D., ... Polman, C. H. (2001). T 1 hypointense lesions in secondary progressive multiple sclerosis: Effect of interferon beta-1b treatment. Brain, 124(7), 1396-1402.

T 1 hypointense lesions in secondary progressive multiple sclerosis : Effect of interferon beta-1b treatment. / Barkhof, Frederik; Van Waesberghe, Jan Hein T M; Filippi, Massimo; Yousry, Tarek; Miller, David H.; Hahn, Dietbert; Thompson, Alan J.; Kappos, Ludwig; Brex, Peter; Pozzilli, Carlo; Polman, Chris H.

In: Brain, Vol. 124, No. 7, 2001, p. 1396-1402.

Research output: Contribution to journalArticle

Barkhof, F, Van Waesberghe, JHTM, Filippi, M, Yousry, T, Miller, DH, Hahn, D, Thompson, AJ, Kappos, L, Brex, P, Pozzilli, C & Polman, CH 2001, 'T 1 hypointense lesions in secondary progressive multiple sclerosis: Effect of interferon beta-1b treatment', Brain, vol. 124, no. 7, pp. 1396-1402.
Barkhof F, Van Waesberghe JHTM, Filippi M, Yousry T, Miller DH, Hahn D et al. T 1 hypointense lesions in secondary progressive multiple sclerosis: Effect of interferon beta-1b treatment. Brain. 2001;124(7):1396-1402.
Barkhof, Frederik ; Van Waesberghe, Jan Hein T M ; Filippi, Massimo ; Yousry, Tarek ; Miller, David H. ; Hahn, Dietbert ; Thompson, Alan J. ; Kappos, Ludwig ; Brex, Peter ; Pozzilli, Carlo ; Polman, Chris H. / T 1 hypointense lesions in secondary progressive multiple sclerosis : Effect of interferon beta-1b treatment. In: Brain. 2001 ; Vol. 124, No. 7. pp. 1396-1402.
@article{b77cc2a2b4704563a6e93ad7ee3901d3,
title = "T 1 hypointense lesions in secondary progressive multiple sclerosis: Effect of interferon beta-1b treatment",
abstract = "Recently, the clinical efficacy of interferon β-1b (IFNβ-1b) was demonstrated for secondary progressive (SP) multiple sclerosis in a European multicentre study. We evaluated the effect of IFNβ-1b treatment on the rate of development of hypointense T 1 MRI lesions, a putative marker of axonal damage. Unenhanced T 1-weighted images were obtained in a subgroup of 95 multiple sclerosis patients from five centres at 6-month intervals; this subgroup was similar to the total study population for all demographic, clinical and MRI parameters. An experienced observer blinded to the clinical data and treatment allocation measured volumes. The median baseline lesion load for hypointense T 1 lesions was 5.1 cm 3 for placebo-treated and 4.9 cm 3 for IFNβ-1b-treated patients (P = 0.56). Placebo-treated patients showed an increase in T 1 lesion load by a median of 14{\%} per year (P = 0.0002 compared with baseline); this was reduced to 7.7{\%} per year in the IFNβ-1b-treated patients (P = 0.003 versus placebo). In the IFNβ-1b arm there was a statistically significant correlation between absolute change in Expanded Disability Status Scale scores and T 1 lesion load by month 36 (r = 0.38, P = 0.0015). In patients with SP multiple sclerosis, IFNβ-1b treatment reduces the development of hypointense T 1 lesions, suggesting that reduced axonal damage in lesions may play a part in the beneficial effect that is observed clinically.",
keywords = "Black holes, Interferon beta, Magnetization transfer, MRI, Multiple sclerosis",
author = "Frederik Barkhof and {Van Waesberghe}, {Jan Hein T M} and Massimo Filippi and Tarek Yousry and Miller, {David H.} and Dietbert Hahn and Thompson, {Alan J.} and Ludwig Kappos and Peter Brex and Carlo Pozzilli and Polman, {Chris H.}",
year = "2001",
language = "English",
volume = "124",
pages = "1396--1402",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - T 1 hypointense lesions in secondary progressive multiple sclerosis

T2 - Effect of interferon beta-1b treatment

AU - Barkhof, Frederik

AU - Van Waesberghe, Jan Hein T M

AU - Filippi, Massimo

AU - Yousry, Tarek

AU - Miller, David H.

AU - Hahn, Dietbert

AU - Thompson, Alan J.

AU - Kappos, Ludwig

AU - Brex, Peter

AU - Pozzilli, Carlo

AU - Polman, Chris H.

PY - 2001

Y1 - 2001

N2 - Recently, the clinical efficacy of interferon β-1b (IFNβ-1b) was demonstrated for secondary progressive (SP) multiple sclerosis in a European multicentre study. We evaluated the effect of IFNβ-1b treatment on the rate of development of hypointense T 1 MRI lesions, a putative marker of axonal damage. Unenhanced T 1-weighted images were obtained in a subgroup of 95 multiple sclerosis patients from five centres at 6-month intervals; this subgroup was similar to the total study population for all demographic, clinical and MRI parameters. An experienced observer blinded to the clinical data and treatment allocation measured volumes. The median baseline lesion load for hypointense T 1 lesions was 5.1 cm 3 for placebo-treated and 4.9 cm 3 for IFNβ-1b-treated patients (P = 0.56). Placebo-treated patients showed an increase in T 1 lesion load by a median of 14% per year (P = 0.0002 compared with baseline); this was reduced to 7.7% per year in the IFNβ-1b-treated patients (P = 0.003 versus placebo). In the IFNβ-1b arm there was a statistically significant correlation between absolute change in Expanded Disability Status Scale scores and T 1 lesion load by month 36 (r = 0.38, P = 0.0015). In patients with SP multiple sclerosis, IFNβ-1b treatment reduces the development of hypointense T 1 lesions, suggesting that reduced axonal damage in lesions may play a part in the beneficial effect that is observed clinically.

AB - Recently, the clinical efficacy of interferon β-1b (IFNβ-1b) was demonstrated for secondary progressive (SP) multiple sclerosis in a European multicentre study. We evaluated the effect of IFNβ-1b treatment on the rate of development of hypointense T 1 MRI lesions, a putative marker of axonal damage. Unenhanced T 1-weighted images were obtained in a subgroup of 95 multiple sclerosis patients from five centres at 6-month intervals; this subgroup was similar to the total study population for all demographic, clinical and MRI parameters. An experienced observer blinded to the clinical data and treatment allocation measured volumes. The median baseline lesion load for hypointense T 1 lesions was 5.1 cm 3 for placebo-treated and 4.9 cm 3 for IFNβ-1b-treated patients (P = 0.56). Placebo-treated patients showed an increase in T 1 lesion load by a median of 14% per year (P = 0.0002 compared with baseline); this was reduced to 7.7% per year in the IFNβ-1b-treated patients (P = 0.003 versus placebo). In the IFNβ-1b arm there was a statistically significant correlation between absolute change in Expanded Disability Status Scale scores and T 1 lesion load by month 36 (r = 0.38, P = 0.0015). In patients with SP multiple sclerosis, IFNβ-1b treatment reduces the development of hypointense T 1 lesions, suggesting that reduced axonal damage in lesions may play a part in the beneficial effect that is observed clinically.

KW - Black holes

KW - Interferon beta

KW - Magnetization transfer

KW - MRI

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0034951507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034951507&partnerID=8YFLogxK

M3 - Article

C2 - 11408334

AN - SCOPUS:0034951507

VL - 124

SP - 1396

EP - 1402

JO - Brain

JF - Brain

SN - 0006-8950

IS - 7

ER -